Details:
ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1 with powerful differentiating effect in hematologic cancer. It is being investigated in with gilteritinib for relapsed/refractory AML harboring a FMS-like tyrosine kinase mutation.
Lead Product(s): Iadademstat,Gilteritinib Fumarate
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
PM534, a novel marine-derived anti-tumor compound, has been tested in the laboratory, both in cell cultures and in animals. In both cases, PM534 showed relevant antitumor activity in a wide variety of tumor types, including those with resistance to other chemotherapies.
Lead Product(s): PM534
Therapeutic Area: Oncology Product Name: PM534
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2022
Details:
The acquisition transforms Synthetic Biologics’ pipeline with the addition of VCN's lead clinical-stage drug candidate, VCN-01, as well as preclinical stage VCN-11, both of which are next-generation OVs in development for the treatment of cancers with high unmet need.
Lead Product(s): VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Theriva Biologics
Deal Size: $4.7 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 11, 2022
Details:
VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma.
Lead Product(s): VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Theriva Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2022
Details:
VCN has the rights to four exclusive patents for proprietary technologies, including VCN-01, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional patents pending.
Lead Product(s): VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Grifols International
Deal Size: $77.4 million Upfront Cash: $4.7 million
Deal Type: Acquisition December 14, 2021
Details:
Immedica gets an exclusive distribution and marketing right of the anti-tumor drug lurbinectedin for territories that include the UK, Ireland, the Nordic countries, Middle East and North Africa.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Immedica Pharma AB
Deal Size: Undisclosed Upfront Cash: $2.1 million
Deal Type: Agreement April 29, 2020